scholarly journals Antidyslipidemic Drug Prescriptions and Lipid Control Status After Unfavorable Annual Health Checkup Results: A Retrospective Cohort Study Using a Health Insurance Database

2021 ◽  
Author(s):  
Kazutaka Nozawa ◽  
Shingo Higa ◽  
Yoichi Ii ◽  
Yuji Yamamoto ◽  
Yuko Asami
Keyword(s):  
Cohort Study ◽  
Health Insurance ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Drug Prescriptions ◽  
Health Checkup ◽  
Health Insurance Database ◽  
Lipid Control ◽  
Insurance Database

scholarly journals Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e029641 ◽  
Author(s):  
Ayumi Takano ◽  
Sachiko Ono ◽  
Hayato Yamana ◽  
Hiroki Matsui ◽  
Toshihiko Matsumoto ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Health Insurance ◽  
Retrospective Cohort Study ◽  
Clinical Guidelines ◽  
Retrospective Cohort ◽  
Neurotic Disorder ◽  
Health Insurance Database ◽  
Insurance Database

ObjectivesCurrent clinical guidelines discourage long-term prescription of benzodiazepines and Z-drugs (BZD); however, the practice continues to exist. The aim of this study was to investigate the proportion of long-term BZD prescriptions and its risk factors.DesignRetrospective cohort study using a health insurance database.SettingJapan.ParticipantsA total of 86 909 patients were identified as outpatients aged 18 to 65 years who started BZD between 1 October 2012 and 1 April 2015. After excluding patients who underwent surgery on the day of first BZD prescription (n=762) and patients without 8 months follow-up (n=12 103), 74 044 outpatients were analysed.Main outcome measuresWe investigated the proportion of long-term prescriptions for ≥8 months among new BZD users. We assessed patient demographics, diagnoses, characteristics of the initial BZD prescription and prescribers as potential predictors of the long-term BZD prescription. Multivariable logistic regression was performed to assess the association between long-term prescription and potential predictors.ResultsOf the new BZD users, 6687 (9.0%) were consecutively prescribed BZD for ≥8 months. The long-term prescription was significantly associated with mood and neurotic disorder, cancer, prescription by psychiatrists, multiple prescriptions, hypnotics and medium half-life BZD in the initial prescription.ConclusionDespite the recent clinical guidelines, 9% of new BZD users were given prescriptions for more than 8 months. Physicians should be aware of risk factors when prescribing BZDs for the first time.

Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study

2013 ◽  
Vol 17 (6) ◽  
pp. 398-403 ◽  
Author(s):  
Annie Levesque ◽  
Jean Lachaine ◽  
Robert Bissonnette
Keyword(s):  
Risk Factors ◽  
Myocardial Infarction ◽  
Cohort Study ◽  
Health Insurance ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Hazard Ratio ◽  
Severe Psoriasis ◽  
Increased Risk ◽  
Insurance Database

Background: Studies have shown that psoriatic patients are at increased risk for myocardial infarction (MI) and stroke. There is a lack of data on MI risk in Canadian psoriatic patients. Objective: To compare MI risk in Canadian psoriatic patients to that in control patients. Methods: This was a retrospective cohort study using Quebec's health insurance database (2005–2010) comparing MI risk in psoriatic patients to that in matched controls. Severe psoriasis was defined as any diagnosed psoriatic patient who used phototherapy or oral or injectable psoriasis treatments. Adjustments were made for several MI risk factors. Results: There were 31,421 patients in the psoriasis population, of which 5,159 had severe psoriasis. The unadjusted MI incidence rate per 1,000 person-years was 4.88 (95% confidence interval [95% CI] 4.50–5.20), 5.58 (95% CI 5.10–6.10), and 5.32 (95% CI 4.40–6.40) for the control and mild and severe psoriasis groups, respectively. After adjustments, the hazard ratio of MI was significantly higher for psoriatic patients than for controls (1.17; 95% CI 1.04–1.31). The hazard ratio was also significantly higher than for controls in the mild psoriasis group (1.18; 95% CI 1.05–1.33) but not in the severe psoriasis group (1.16; 95% CI 0.94–1.42). Conclusion: The relative MI risk is higher for Canadian psoriatic patients than for controls.

scholarly journals Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan

2021 ◽  
pp. annrheumdis-2021-220439
Author(s):  
Ruriko Koto ◽  
Akihiro Nakajima ◽  
Hideki Horiuchi ◽  
Hisashi Yamanaka
Keyword(s):  
Uric Acid ◽  
Cohort Study ◽  
Health Insurance ◽  
Serum Uric Acid ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Disease Status ◽  
Insurance Claims ◽  
Health Insurance Claims ◽  
Gout Flare

ObjectivesIn patients with gout, treating to target serum uric acid levels (sUA) of ≤6.0 mg/dL is universally recommended to prevent gout flare. However, there is no consensus on asymptomatic hyperuricaemia. Using Japanese health insurance claims data, we explored potential benefits of sUA control for preventing gout flare in subjects with asymptomatic hyperuricaemia.MethodsThis retrospective cohort study analysed the JMDC Claims Database from April 2012 through June 2019. Subjects with sUA ≥8.0 mg/dL were identified, and disease status (prescriptions for urate-lowering therapy (ULT), occurrence of gout flare, sUA) was investigated for 1 year. Time to first onset and incidence rate of gout flare were determined by disease status subgroups for 2 years or more. The relationship between gout flare and sUA control was assessed using multivariable analysis.ResultsThe analysis population was 19 261 subjects who met eligibility criteria. We found fewer occurrences of gout flare, for both gout and asymptomatic hyperuricaemia, in patients who achieved sUA ≤6.0 mg/dL with ULT than in patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. In particular, analysis by a Cox proportional-hazard model for time to first gout flare indicated that the HR was lowest, at 0.45 (95% CI 0.27 to 0.76), in subjects with asymptomatic hyperuricaemia on ULT (5.0<sUA ≤ 6.0 mg/dL), compared with untreated subjects (sUA ≥8.0 mg/dL).ConclusionsOccurrences of gout flare were reduced by controlling sUA at ≤6.0 mg/dL in subjects with asymptomatic hyperuricaemia as well as in those with gout.Trial registration numberUMIN000039985.

scholarly journals Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study

2019 ◽  
Vol 29 (1) ◽  
Author(s):  
Karin Lisspers ◽  
Kjell Larsson ◽  
Christer Janson ◽  
Björn Ställberg ◽  
Ioanna Tsiligianni ◽  
...  
Keyword(s):  
Primary Care ◽  
Gender Differences ◽  
Cohort Study ◽  
Mortality Rate ◽  
Real World ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Healthcare Resource ◽  
Drug Prescriptions ◽  
Copd Patients

AbstractThe present study aimed to generate real-world evidence regarding gender differences among chronic obstructive pulmonary disease (COPD) patients, especially as regards the diagnosis and outcomes in order to identify areas for improvement and management and optimize the associated healthcare resource allocation. ARCTIC is a large, real-world, retrospective cohort study conducted in Swedish COPD patients and a matched reference population from 52 primary care centers in 2000–2014. The incidence of COPD, prevalence of asthma and other comorbidities, risk of exacerbations, mortality rate, COPD drug prescriptions, and healthcare resource utilization were analyzed. In total, 17,479 patients with COPD were included in the study. During the study period, COPD was more frequent among women (53.8%) and women with COPD experienced more exacerbations vs. men (6.66 vs. 4.66). However, the overall mortality rate was higher in men compared with women (45% vs. 38%), but no difference for mortality due to COPD was seen between genders over the study period. Women seemed to have a greater susceptibility to asthma, fractures, osteoporosis, rheumatoid arthritis, rhinitis, depression, and anxiety, but appeared less likely to have diabetes, kidney diseases, and cardiovascular diseases. Furthermore, women had a greater risk of COPD-related hospitalization and were likely to receive a significantly higher number of COPD drug prescriptions compared with men. These results support the need to reduce disease burden among women with COPD and highlight the role of healthcare professionals in primary care who should consider all these parameters in order to properly diagnose and treat women with COPD.

Sign in / Sign up

Export Citation Format

Share Document